Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

OncoC4 Receives FDA Fast Track Designation for Cesalatamig, an Investigational PD-1 ...

16 September 2026 · By · Wire by Fusion42

Published

16 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 16 September 2026 · Fusion42 review

OncoC4's investigational bispecific antibody Cesalatamig has received FDA Fast Track designation, accelerating its regulatory review process for cancer treatment.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Biotech founders targeting cancer treatments can now accelerate clinical timelines with the Fast Track status for bispecific antibodies. Prepare to engage US regulators early to capitalise on smoother approval paths.

◆ Coverage

1 source · 16 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfdafast-trackoncologybiotechregulatory